跳至主要内容
临床试验/NCT02005341
NCT02005341撤回不适用

A Prospective, Nonrandomized Study to Assess Lumbar Fusion With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive

Pioneer Surgical Technology, Inc.0 个研究点开始时间: 2011年10月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
主要终点
Fusion at 12 months postoperatively.

研究概览

简要总结

The purpose of this study is to assess lumbar fusion using nanOss Bioactive bone void filler

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Is at least 21 years of age and skeletally mature.
  • Must have cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one level in the cervical spine between C3 to T
  • Must have completed a minimum of six weeks of unsuccessful conservative, non-operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment.
  • Has pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (Anteroposterior/Lateral/Flexion/Extension X-rays & a recent MRI).
  • Is willing and able to comply with all clinical investigation visits and procedures including screening treatment procedures, post-operative management, the follow-up schedule and completion of forms or questionnaires.
  • Is able to understand and sign the patient information sheet/informed consent form.

排除标准

  • Requires fusion at more than one level.
  • Has had prior fusion at the level to be treated.
  • Has a metabolic or systemic bone disorder.
  • Has a disease that significantly inhibits bone healing (i.e., severe osteoporosis, osteomalacia, Paget's disease).
  • Has a systemic or local infection (active or latent).
  • Has acute or chronic infections in the surgical area (i.e., soft tissue infections; inflammatory, bacterial bone disorders, osteomyelitis).
  • Chronic use of steroids, other than episodic use or inhaled corticosteroids.
  • Has any significant general illness (i.e., HIV, active metastatic cancer of any type, uncontrolled diabetes Type I, dialysis dependent renal failure, symptomatic liver disease).
  • Has a mental or physical condition that would limit the ability to comply with study requirements or would preclude accurate evaluation.
  • Is immunocompromised or being treated with immunosuppressive agents (including chemotherapy or radiation treatment).
  • Has documented allergies to hydroxyapatite or porcine collagen, PEEK, titanium, titanium alloy or tantalum.
  • Is currently pregnant, or interested in becoming pregnant during the clinical investigation follow-up.
  • Is a smoker.
  • Is non-English speaking.
  • Requires the use of a bone-growth stimulator.
  • Is a prisoner.
  • Is currently involved in another drug or device clinical investigation that may confound the clinical trial investigation

结局指标

主要结局

Fusion at 12 months postoperatively.

时间窗: 12 months

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验